Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
(KAPA) LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company’s interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Interest
Related Questions
How will the interim efficacy results of ENV105 influence KAPA's valuation and short‑term stock momentum?
What are the potential regulatory and commercial timelines for ENV105 compared to other advanced prostate cancer therapies?
How might the KOL event feedback affect investor sentiment and the likelihood of upcoming partnership or licensing deals?